Hybrid Pharma Sales Rep — Remote & Field Engagements

Amplity; Michigan; Hybrid; USD 60,000 - 90,000; Full time

Job summary

Amplity is seeking a Hybrid Sales Representative to engage customers through remote and in-person channels and promote brand messaging. You will build and maintain relationships with targeted accounts, using digital tools and data to drive ongoing dialogue and territory growth.

The role emphasizes qualified pharmaceutical sales experience, expertise in therapeutic areas, and the use of digital resources to maximize reach and impact. Travel up to 30% is expected.

Qualifications

• Bachelor’s degree from an accredited university or college.
• Pharmaceutical sales experience required.
• 1+ years Therapeutic area experience preferred.
• Virtual Sales experience required.
• Specialty Pharmaceutical experience required.
• Experience utilizing digital resources, triggers/suggestions.
• Certified on product by client preferred.

Responsibilities

• Manage daily sales call activity across territories including remote and Face to Face engagements.
• Engage with healthcare professionals (HCPs) face to face as opportunities arise.
• Utilize digital resources and technology to connect with HCPs.
• Develop and manage targeted lists of HCPs and implement business plans to achieve territory goals.
• Communicate effectively to customers using professional selling and negotiation skills.

Skills

Communication skills

Virtual sales

Therapeutic area experience

Specialty pharma experience

Digital resources utilization

Education

Bachelor’s degree

Job description

Amplity is seeking a Hybrid Sales Representative to engage customers through remote and in-person channels and promote brand messaging. You will build and maintain relationships with targeted accounts, using digital tools and data to drive ongoing dialogue and territory growth.

The role emphasizes qualified pharmaceutical sales experience, expertise in therapeutic areas, and the use of digital resources to maximize reach and impact. Travel up to 30% is expected.